Full Text View
Tabular View
No Study Results Posted
Related Studies
Psychoeducation for Hepatitis and Alcohol Behaviors
This study is currently recruiting participants.
Study NCT00598416   Information provided by National Institute on Alcohol Abuse and Alcoholism (NIAAA)
First Received: January 10, 2008   Last Updated: September 15, 2008   History of Changes

January 10, 2008
September 15, 2008
September 2006
August 2011   (final data collection date for primary outcome measure)
Increased treatment readiness and better treatment adherence for treatment of HCV. [ Time Frame: Index, Post intervention, and 1 year follow-up ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT00598416 on ClinicalTrials.gov Archive Site
  • Better management of substance abuse and other psychiatric disorders. [ Time Frame: Index, Post intervention, and 1 year follow up ] [ Designated as safety issue: No ]
  • Better social functioning and increased quality of life. [ Time Frame: Index, Post intervention, and 1 year follow up ] [ Designated as safety issue: No ]
Same as current
 
Psychoeducation for Hepatitis and Alcohol Behaviors
Psychoeducation for HCV and Alcohol Behaviors

The proposed project will apply a unique, effective family-responsive psychoeducation program, PsychoEducation Responsive to Families (PERF), for Hepatitis C Virus (HCV) treatment. The goal is to demonstrate that the intervention will enlarge the eligibility of some patients for HCV treatment and help sustain others through it.

This study aims to evaluate the utility of a psychosocial intervention (PsychoEducation Responsive to Families; PERF), applied to help patients prepare for and sustain HCV treatment in the treatment setting. Through careful psychiatric diagnosis and multiple longitudinal assessments, this study will also shed further light on the course of comorbid alcohol use, drug use, and other psychiatric syndromes and their interrelationships. The proposed study combines an innovative psychoeducation program with traditional HCV patient care and education. The goal of this work is to improve treatment adherence, allowing individual drug regimens to achieve their optimal effectiveness and reach a wider patient population. Support and sustenance of patients from a psychosocial perspective while they are in treatment should also help deliver more patients to sustained suppression of HCV as well as help presently untreated patients and populations become candidates for this therapy—ultimately reducing the disease burden of increasing numbers of patients needing liver transplantation or facing imminent death.

 
Interventional
Supportive Care, Randomized, Double Blind (Subject, Caregiver, Outcomes Assessor), Parallel Assignment, Efficacy Study
  • Hepatitis C
  • Substance Abuse
Behavioral: Family-Responsive Psychoeducation Program (PERF)
 
 

*   Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
 
Recruiting
400
August 2011
August 2011   (final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Individuals who are seropositive for HCV as determined by ELISA test and confirmed by direct measure of viral load as part of their clinical care
  2. Lack progressive or decompensated liver functions (manifest in jaundice, ascites, variceal bleeding, hepatic encephalopathy)
  3. Age at least 18 years
  4. Identified family member(s)/significant other(s) also willing to participate in the psychoeducation groups, and
  5. Ability to provide informed consent for research participation. "Family" will be defined to include biological relatives, as well as any non-biological individual or significant other considered "family" by either the ill member or his/her immediate family.

Exclusion Criteria:

  1. Inability to provide informed consent such as irreversible cognitive impairment precluding participation
  2. Progressive or decompensated liver functions (manifest in jaundice, ascites, variceal bleeding, hepatic encephalopathy), and
  3. Age <18 years.
Both
18 Years and older
No
Contact: Dana Downs, MA, MSW 214-648-5378 Dand.Downs@UTSouthwestern.edu
United States
 
NCT00598416
Carol S. North, MD, MPE, University of Texas Southwestern Medical School
NIAAA-NORTH-AA015201, R01-AA015201
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
 
Principal Investigator: Carol S North, MD, MPE Univeristy of Texas Southwestern Medical Center
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
September 2008

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP